News & Updates
Showing Pharmacy articles
Showing
Show Multimedia Only

ANTHEM-UC unlocks psoriasis drug potential in ulcerative colitis
26 May 2026
byAudrey Abella
Icotrokinra—the first and only targeted oral peptide designed to selectively block the interleukin-23 receptor (IL-23R), which has been approved for the treatment of plaque psoriasis—shows multiple favourable signals for the treatment of ulcerative colitis (UC), according to updated data from the phase IIb ANTHEM-UC study.
ANTHEM-UC unlocks psoriasis drug potential in ulcerative colitis
26 May 2026
Long-term dupilumab blocks relapse in moderate-to-severe atopic dermatitis
25 May 2026
byStephen Padilla
The use of dupilumab significantly delays disease relapse in patients with moderate-to-severe atopic dermatitis (AD) while having an acceptable safety profile, reports a study.







